Skip to main content
. 2018 Mar 7;8(2):131–136. doi: 10.1016/j.apsb.2018.01.012

Figure 1.

Fig. 1

Classical ARV drugs in phase III clinical trials. (A) Tenofovir alafenamide (GS-7340, Vemlidy, C21H29N6O5P), a nucleotide reverse transcriptase inhibitor and a prodrug of tenofovir. (B) Doravirine (MK-1439, C17H11ClF3N5O3), a non-nucleoside reverse transcriptase inhibitor. (C) Bictegravir (BIC, GS-9883, C21H18F3N3O5), an integrase inhibitor.